- Home
- ANTA vs PLX Comparison
ANTA vs PLX Comparison
Compare ANTA & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANTA | PLX |
|---|---|---|
| Founded | 2022 | 1993 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.7M | 174.0M |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | ANTA | PLX |
|---|---|---|
| Price | $8.16 | $2.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $16.17 | $12.00 |
| AVG Volume (30 Days) | 9.3K | ★ 961.8K |
| Earning Date | 03-03-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $52,744,000.00 |
| Revenue This Year | $27.57 | $36.81 |
| Revenue Next Year | $30.46 | $1.77 |
| P/E Ratio | $19.77 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.25 | $1.34 |
| 52 Week High | $15.65 | $3.19 |
Technical Indicators
Market Signals| Indicator | ANTA | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 55.08 | 46.51 |
| Support Level | $6.53 | $2.03 |
| Resistance Level | $10.00 | $2.45 |
| Average True Range (ATR) | 0.70 | 0.09 |
| MACD | 0.22 | 0.03 |
| Stochastic Oscillator | 52.91 | 91.53 |
Price Performance
Historical ComparisonAbout ANTA Antalpha Platform Holding Company Ordinary Shares
Antalpha Platform Holding Co provides financing, technology and risk management solutions to the digital asset industry. It is a provider of supply chain financing solutions to institutional and corporate participants in the Bitcoin mining industry, offering loans secured by Bitcoin and Bitcoin mining machines. It has developed a technology platform, Antalpha Prime, which enables customers to apply for and manage their digital asset loans while allowing to closely monitor collateral positions.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.